Abcellera Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Abcellera Biologics
ABCL Stock  USD 3.23  0.03  0.94%   
Abcellera Biologics financial statements provide useful quarterly and yearly information to potential Abcellera Biologics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Abcellera Biologics financial statements helps investors assess Abcellera Biologics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Abcellera Biologics' valuation are summarized below:
Gross Profit
-136.8 M
Market Capitalization
954 M
Enterprise Value Revenue
11.598
Revenue
33 M
Earnings Share
(0.61)
There are over one hundred nineteen available fundamental signals for Abcellera Biologics, which can be analyzed over time and compared to other ratios. We recommend to validate Abcellera Biologics' prevailing fundamental drivers against the all of the trends between 2010 and 2025. The value of Market Cap is estimated to slide to about 1.8 B. The Enterprise Value is projected to slide to about 1.7 B

Abcellera Biologics Total Revenue

41.54 Million

Check Abcellera Biologics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Abcellera Biologics' main balance sheet or income statement drivers, such as Net Interest Income of 51 M, Interest Income of 51 M or Depreciation And Amortization of 37.3 M, as well as many indicators such as Price To Sales Ratio of 47.44, Dividend Yield of 0.0 or PTB Ratio of 1.57. Abcellera financial statements analysis is a perfect complement when working with Abcellera Biologics Valuation or Volatility modules.
  
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.

Abcellera Biologics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets989.6 M1.7 B516.9 M
Slightly volatile
Short and Long Term Debt Total93.4 M89 M26.4 M
Slightly volatile
Other Current Liabilities50.4 M78.6 M25.3 M
Slightly volatile
Total Current Liabilities87.2 M136.9 M47 M
Slightly volatile
Total Stockholder Equity781.7 M1.3 B404 M
Slightly volatile
Other Liabilities69.6 M129.5 M40.5 M
Slightly volatile
Net Tangible Assets1.3 B1.2 B384.1 M
Slightly volatile
Property Plant And Equipment Net347.4 M330.9 M86.1 M
Slightly volatile
Current Deferred Revenue11 M21.8 M7 M
Slightly volatile
Accounts Payable15.2 M29.3 M8.7 M
Slightly volatile
Cash294.8 M153.3 M133.7 M
Slightly volatile
Non Current Assets Total744 M708.5 M202 M
Slightly volatile
Long Term Debt1.6 M2.5 M1.4 M
Slightly volatile
Cash And Short Term Investments546.7 M874.7 M280.4 M
Slightly volatile
Net Receivables89 M74 M42.6 M
Slightly volatile
Common Stock Total Equity479 M844.5 M267.2 M
Slightly volatile
Common Stock Shares Outstanding290.3 M332.5 M256.8 M
Slightly volatile
Liabilities And Stockholders Equity989.6 M1.7 B516.9 M
Slightly volatile
Non Current Liabilities Total261.7 M249.3 M74.8 M
Slightly volatile
Other Current Assets31.7 M52.8 M16.4 M
Slightly volatile
Other Stockholder Equity146.2 M139.2 M34.5 M
Slightly volatile
Total Liabilities208 M386.1 M113 M
Slightly volatile
Net Invested Capital780.7 M1.3 B401.5 M
Slightly volatile
Property Plant And Equipment Gross384.4 M366 M94.3 M
Slightly volatile
Short and Long Term Debt162.4 K171 K1.6 M
Slightly volatile
Total Current Assets672.5 M1 B341.6 M
Slightly volatile
Capital Stock540 M866.2 M278.3 M
Slightly volatile
Non Current Liabilities Other6.5 M6.8 M10.5 M
Pretty Stable
Net Working Capital585.3 M865.9 M294.6 M
Slightly volatile
Short Term Debt4 M7.1 M3.3 M
Slightly volatile
Common Stock537.3 M866.2 M273.4 M
Slightly volatile
Property Plant Equipment262.3 M249.8 M71.4 M
Slightly volatile
Non Currrent Assets Other113.8 M108.4 M25.4 M
Slightly volatile
Other Assets102 M97.1 M26.9 M
Slightly volatile
Inventory1.3 M1.3 M619.8 K
Slightly volatile
Good Will48.1 M55 M37.1 M
Slightly volatile
Short Term Investments541.2 M721.4 M573.2 M
Pretty Stable
Long Term Investments57.2 M75.8 M33.3 M
Slightly volatile
Intangible Assets103.1 M108.4 M117.4 M
Pretty Stable
Retained Earnings Total Equity381.6 M490.1 M308.5 M
Slightly volatile
Capital Surpluse60.2 M85.2 M44.9 M
Slightly volatile
Deferred Long Term Liabilities28.2 M29.9 M35.8 M
Slightly volatile

Abcellera Biologics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income51 M48.6 M10.1 M
Slightly volatile
Depreciation And Amortization37.3 M35.5 M9.7 M
Slightly volatile
Interest Expense2.5 M4.7 M1.5 M
Slightly volatile
Selling General Administrative73.7 M70.1 M18.6 M
Slightly volatile
Selling And Marketing Expenses17.1 M16.3 M4.5 M
Slightly volatile
Total Revenue41.5 M43.7 M59 M
Slightly volatile
Gross Profit41.5 M43.7 M52.6 M
Slightly volatile
Other Operating Expenses332.3 M316.5 M84.4 M
Slightly volatile
Research Development212.1 M202 M53.2 M
Slightly volatile
Total Operating Expenses332.3 M316.5 M78.6 M
Slightly volatile
Reconciled Depreciation37.3 M35.5 M10.6 M
Slightly volatile
Non Recurring61.6 M76.4 M51.1 M
Slightly volatile
Non Operating Income Net Other20.5 M26 M16.8 M
Slightly volatile

Abcellera Biologics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation77.5 M73.8 M19.4 M
Slightly volatile
Depreciation37.3 M35.5 M10.6 M
Slightly volatile
Capital Expenditures93.6 M89.1 M28.6 M
Slightly volatile
End Period Cash Flow309.6 M184.7 M141.6 M
Slightly volatile
Change To Netincome67.5 M64.3 M18.5 M
Slightly volatile
Dividends Paid11.3 K12.7 K13.9 K
Slightly volatile
Cash Flows Other Operating117.5 M176 M83 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio47.4449.94953
Slightly volatile
PTB Ratio1.571.65735
Slightly volatile
Days Sales Outstanding584556179
Slightly volatile
Book Value Per Share2.033.591.3274
Slightly volatile
Stock Based Compensation To Revenue1.61.520.3582
Slightly volatile
Capex To Depreciation3.452.894.4631
Slightly volatile
PB Ratio1.571.65735
Slightly volatile
EV To Sales45.8348.24952
Slightly volatile
Inventory Turnover41.7849.8752.8319
Slightly volatile
Days Of Inventory On Hand7.467.584.3812
Slightly volatile
Payables Turnover4.665.154.13
Slightly volatile
Sales General And Administrative To Revenue1.521.440.4544
Slightly volatile
Average Inventory65.2 K73.4 K80 K
Slightly volatile
Research And Ddevelopement To Revenue4.374.161.278
Slightly volatile
Capex To Revenue1.931.830.745
Slightly volatile
Cash Per Share1.422.370.9251
Slightly volatile
Days Payables Outstanding72.773.3290.3651
Slightly volatile
Intangibles To Total Assets0.140.130.1408
Slightly volatile
Current Ratio4.746.594.1063
Slightly volatile
Tangible Book Value Per Share1.73.061.1195
Slightly volatile
Receivables Turnover0.650.684.9991
Slightly volatile
Graham Number3.556.062.2846
Slightly volatile
Shareholders Equity Per Share2.033.591.3274
Slightly volatile
Debt To Equity0.07340.07720.2293
Slightly volatile
Capex Per Share0.250.240.0941
Slightly volatile
Average Receivables1.4 M1.6 M1.7 M
Slightly volatile
Revenue Per Share0.110.120.2937
Slightly volatile
Interest Debt Per Share0.250.240.0902
Slightly volatile
Debt To Assets0.110.05980.1277
Slightly volatile
Short Term Coverage Ratios11310744.4863
Slightly volatile
Operating Cycle584556182
Slightly volatile
Price Book Value Ratio1.571.65735
Slightly volatile
Days Of Payables Outstanding72.773.3290.3651
Slightly volatile
Company Equity Multiplier1.681.491.6975
Slightly volatile
Long Term Debt To Capitalization0.00290.0030.0493
Slightly volatile
Total Debt To Capitalization0.140.07240.1775
Slightly volatile
Debt Equity Ratio0.07340.07720.2293
Slightly volatile
Quick Ratio4.736.594.1012
Slightly volatile
Net Income Per E B T0.890.970.9853
Slightly volatile
Cash Ratio0.961.011.9757
Pretty Stable
Days Of Inventory Outstanding7.467.584.3812
Slightly volatile
Days Of Sales Outstanding584556179
Slightly volatile
Price To Book Ratio1.571.65735
Slightly volatile
Fixed Asset Turnover0.140.152.0595
Very volatile
Debt Ratio0.110.05980.1277
Slightly volatile
Price Sales Ratio47.4449.94953
Slightly volatile
Asset Turnover0.02790.02940.3192
Slightly volatile
Gross Profit Margin0.50.780.499
Slightly volatile
Price Fair Value1.571.65735
Slightly volatile

Abcellera Biologics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.8 B1.9 B7.1 B
Slightly volatile
Enterprise Value1.7 B1.8 B7 B
Slightly volatile

Abcellera Fundamental Market Drivers

Forward Price Earnings27.4725
Cash And Short Term Investments760.6 M

Abcellera Upcoming Events

20th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
20th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Abcellera Biologics Financial Statements

Abcellera Biologics investors utilize fundamental indicators, such as revenue or net income, to predict how Abcellera Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue21.8 M11 M
Total Revenue43.7 M41.5 M
Cost Of Revenue35.5 M33 M
Stock Based Compensation To Revenue 1.52  1.60 
Sales General And Administrative To Revenue 1.44  1.52 
Research And Ddevelopement To Revenue 4.16  4.37 
Capex To Revenue 1.83  1.93 
Revenue Per Share 0.12  0.11 
Ebit Per Revenue(7.17)(6.82)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Abcellera Biologics is a strong investment it is important to analyze Abcellera Biologics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Abcellera Biologics' future performance. For an informed investment choice regarding Abcellera Stock, refer to the following important reports:
How To Invest In Abcellera
Details
Is Abcellera Stock a good investment?
Details
What is Abcellera Biologics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Abcellera Biologics Correlation against competitors.
For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.
You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.459
Earnings Share
(0.61)
Revenue Per Share
0.112
Quarterly Revenue Growth
(0.01)
Return On Assets
(0.13)
The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY